Kao Opens New Tertiary Amine Production Plant in U.S. to Meet Global Growing Demand
25.8.2025 08:10:00 CEST | Business Wire | Press Release
Kao Corporation (TOKYO:4452) (President and CEO: Yoshihiro Hasebe) has built a new tertiary amine production plant in Pasadena, Texas, United States, the opening ceremony for which took place on August 22, 2025. The new plant, with an annual production capacity of 20,000 tons, will further enhance stable supply for the U.S. market, which is expected to grow in the mid- to long-term. In addition, local production in the U.S. will improve the efficiency of Kao’s supply chain and reduce transportation-related CO2 emissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250824920248/en/
New tertiary amine production plant in Texas
Tertiary amines are important chemical ingredients used in surfactants such as disinfectants and cleaners. Until now, Kao has had the world’s largest production capacity, with three production sites in Japan, the Philippines and Germany employing Kao’s unique technology to produce tertiary amines of superior quality. Kao uses tertiary amines in its own products and has also supplied industries around the world through its Chemical Business. Its new U.S. plant will create a three-production-site system with plants in the U.S., Europe and Asia, to ensure a more stable and speedier supply of tertiary amines to global markets.
For Kao’s Chemical Business, tertiary amines are a core component of Global Sharp Top*1, the focus of Kao’s Mid-term Plan 2027 (K27). The new plant will make a major contribution to ensure further stability of the Chemical Business’s global business base.
*1
“Global Sharp Top” is Kao’s business strategy for achieving meaningful and sustainable global growth by focusing on businesses that deliver critical solutions in markets facing rapidly evolving social challenges.
Comment from Daisuke Hamada, President, Chemical Business
Construction work on the Pasadena plant took two and a half years, and I am very happy to see the work successfully completed. The plant, which combines Kao’s unique technologies with a long-running safety record and quality control knowhow, will be the key point of a global supply chain ensuring a more stable supply of tertiary amines not only for the North American market but also for a broad range of industries all over the world.
The Pasadena site, where the plant is located, covers an area of 45 hectares, and Kao is also considering utilizing the site not only for tertiary amine production but also as a platform for working together with outside partners to produce derivatives. By leveraging this platform, we are confident it will strengthen the value chain of the entire ecosystem.
The Chemical Business will continue resolutely taking on the challenges to fulfill its role in building the cornerstone of Kao’s global growth.
About Kao
Kao, a Japan-based manufacturer of personal care and household products, cosmetics, and specialty chemicals creates high-value-added products and services that provide care and enrichment for the life of all people and the planet. Through its brands such as Attack, Bioré, Jergens, Laurier, Curél, SENSAI, MOLTON BROWN, and Oribe, Kao is part of the everyday lives of people across Asia, the Americas, Europe, the Middle East, and Africa. The Chemical Business also contributes to a wide range of industries. Utilizing its capabilities in precise interface control technology, the Chemical Business applies its deep knowledge in the areas of fats and oils and polymers to provide a variety of products and solutions. From daily necessities to electronic materials, agricultural products, asphalt additives and more, Kao works to provide solutions for broad industry needs and social issues. With about 1,630 billion yen in annual sales, Kao employs about 32,600 people worldwide and has more than 130 years of history in innovation.
Please visit the Kao Group website for additional information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250824920248/en/
Contacts
Media inquiries should be directed to:
Public Relations
Kao Corporation
corporate_pr@kao.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom